Opportunities exist to develop drugs with a durable weight-loss effect in the absence of ongoing pharmacotherapy which would be greatly attractive to patients
G., Vernacotola, S., Mariotti, P., Bianchi, E., Calvani, M., De Gaetano, A., Chiurazzi, P., and Neri, G
Compounders can make drugs when a patients needs cant be met by an existing FDA-approved drugsay, theyre allergic to a dye or binding agent in it or they cant swallow pills or take it in whatever form is availableor when theres a shortage of an FDA-approved drug
426431, Oct
Immunity 51 (6), 983996.e6
Specifically in regard to nausea, it tended to be most pronounced in the first 4 weeks of therapy in all phase III LEAD trials, with symptoms generally dissipating over the remainder of the study period